$20.54
Bicycle Therapeutics is a biotechnology business based in the US. Bicycle Therapeutics shares (BCYC) are listed on the NASDAQ and all prices are listed in US Dollars. Bicycle Therapeutics employs 284 staff and has a trailing 12-month revenue of around $39.6 million.
Our top picks for where to buy Bicycle Therapeutics stock
How to buy Bicycle Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BCYC. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Bicycle Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Bicycle Therapeutics stock price (NASDAQ: BCYC)
Use our graph to track the performance of BCYC stocks over time.Bicycle Therapeutics shares at a glance
Latest market close | $20.54 |
---|---|
52-week range | $12.54 - $27.24 |
50-day moving average | $22.33 |
200-day moving average | $21.09 |
Wall St. target price | $38.63 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-3.76 |
Is it a good time to buy Bicycle Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Bicycle Therapeutics price performance over time
Historical closes compared with the close of $20.54 from 2024-09-06
1 week (2024-08-30) | -4.47% |
---|---|
1 month (2024-08-07) | -8.91% |
3 months (2024-06-07) | -10.85% |
6 months (2024-03-07) | -18.94% |
1 year (2023-09-07) | -1.63% |
---|---|
2 years (2022-09-07) | -18.91% |
3 years (2021-09-07) | 40.27 |
5 years (2019-09-06) | 202.95% |
Bicycle Therapeutics financials
Revenue TTM | $39.6 million |
---|---|
Gross profit TTM | $-67,146,000 |
Return on assets TTM | -15.17% |
Return on equity TTM | -30.24% |
Profit margin | 0% |
Book value | $12.68 |
Market Capitalization | $1.5 billion |
TTM: trailing 12 months
Bicycle Therapeutics share dividends
We're not expecting Bicycle Therapeutics to pay a dividend over the next 12 months.
Bicycle Therapeutics share price volatility
Over the last 12 months, Bicycle Therapeutics's shares have ranged in value from as little as $12.54 up to $27.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bicycle Therapeutics's is 0.885. This would suggest that Bicycle Therapeutics's shares are less volatile than average (for this exchange).
Bicycle Therapeutics overview
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Frequently asked questions
nullWhat percentage of Bicycle Therapeutics is owned by insiders or institutions?
Currently 1.308% of Bicycle Therapeutics shares are held by insiders and 90.738% by institutions. How many people work for Bicycle Therapeutics?
Latest data suggests 284 work at Bicycle Therapeutics. When does the fiscal year end for Bicycle Therapeutics?
Bicycle Therapeutics's fiscal year ends in December. Where is Bicycle Therapeutics based?
Bicycle Therapeutics's address is: Portway Building, Cambridge, United Kingdom, CB21 6GS What is Bicycle Therapeutics's ISIN number?
Bicycle Therapeutics's international securities identification number is: US0887861088 What is Bicycle Therapeutics's CUSIP number?
Bicycle Therapeutics's Committee on Uniform Securities Identification Procedures number is: 088786108
More guides on Finder
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
7 best day trading platforms of 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Trading for beginners: 11 best trading platforms to get started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 best discount brokers of 2024 for low-cost trading and investing
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
10 best stock apps of 2024 to elevate your mobile trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
5 top graphene stocks to invest in today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question